Inozyme Pharma, Inc. stock is up 24.48% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 December’s closed higher than November.
Inozyme Pharma, Inc. engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.